Feature | July 25, 2013

First Robotic-Assisted STEMI Stent Performed at Sanford Aberdeen Medical Center

Interventional cardiologist performs CorPath Robotic angioplasty, door-to-balloon time superior to national average

CorPath Robotic Angioplasty Corindus Sanford Aberdeen Medical Center South Dakot

July 25, 2013 — Sanford Aberdeen Medical Center in Aberdeen, S.D. became the first hospital to perform a robotic angioplasty for a patient with an acute heart attack, achieving a far better door-to-balloon time than the national standard. Interventional cardiologist Puneet Sharma, performed the percutaneous coronary intervention (PCI) to treat a patient that had experienced a heart attack and presented to the Sanford Aberdeen emergency department. Utilizing the U.S. Food and Drug Administration (FDA)-cleared CorPath System, Sharma was able to perform the robotic-assisted angioplasty procedure and restore blood flow to the patient’s heart within 68 minutes of their arrival.

The current nationwide standard for door-to-balloon time — from when a patient with a heart attack is presented to the emergency department (ED) to inflating a balloon in his coronary arteries to restore blood flow to the heart — is 90 minutes. These standards were developed by the American College of Cardiology (ACC) to improve timely access to the cath lab and by that improving clinical outcome.

“Timely access to emergency cardiac care and survival is partly dependent on access to services and technology,” said Sharma. “Being able to perform a CorPath Robotic Angioplasty on a STEMI patient within 68 minutes is a great benefit. As shown with the latest procedure, robotic-assisted angioplasties improve rural access and quality of care as more patients in this area will have access for advanced specialty care. The implementation of the CorPath System and its ability to precisely and rapidly execute an angioplasty procedure with only one stent in the patient heart is a great example of Sanford Health’s commitment to enhanced clinical outcome for our patients.”

The CorPath System is the first and only FDA cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Seated in an interventional cockpit, the interventional cardiologist advances stents and guidewires via a joystick with millimeter-by-millimeter precision. The system, which is quickly being adopted as the new standard of care in coronary angioplasty procedures, may also improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.

Sanford Health performs robotic-assisted angioplasty procedures with the CorPath System at both Sanford Heart Hospital in Sioux Falls and Sanford Aberdeen Medical Center. It is the first and only health system in the region utilizing the CorPath System.

For more information: www.corindus.com

Related Content

HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
PCI, OFDI, OCT, optical coherence tomography, optimal frequency domain imaging, EuroPCR 2016 study
News | Intravascular Imaging| May 20, 2016
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
St. Jude Medical, EuroPCR 2016 studies, FFR, LAAO, left atrial appendage occlusion, fractional flow reserve, Amplatzer
News | Cath Lab| May 19, 2016
St. Jude Medical Inc. announced results from two cardiovascular clinical trials presented at EuroPCR 2016.
clot, coronary thrombus, antiplatelet therapt, DAPT

An intravascular ultrasound (IVUS) image of a thrombus formed in a coronary artery.  While there are guidelines for antiplatelet therapy, there are still questions over the duration of such therapy. 

Feature | Antiplatelet and Anticoagulation Therapies| May 19, 2016 | Marianne Pop, Pharm.D., BCPS
There are many opinions on the duration of dual antiplatelet therapy (DAPT), highlighted at the 2016 American College
bioabsorbable vascular graft, children, feasibility study, Bakoulev Center Moscow, AATS 2016 meeting

Image courtesy of Bakoulev Scientific Center for Cardiovascular Surgery

News | Stent Grafts| May 18, 2016
Bioabsorbable heart valves or blood vessels are designed to harness the body’s innate healing process, enabling the...
NeoChord, DS1000 System, FDA approval, U.S. pivotal trial
News | Heart Valve Technology| May 17, 2016
NeoChord Inc. announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
Biotronik, Magmaris bioresorbable magnesium scaffold, BIOSOLVE-II Trial, 12-month results, EuroPCR 2016
News | Stents Bioresorbable| May 17, 2016
Biotronik presented 12-month data from the BIOSOLVE-II trial during a Hotline Session at EuroPCR 2016.

Biosensors' Biomatrix stent.

Feature | Stents| May 16, 2016
May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables Co

A Medtronic CoreValve TAVR device being deployed under angiographic image guidance.

 

Feature | Heart Valve Technology| May 16, 2016
 
Overlay Init